Aprea Therapeutics, Inc. Common stock APRE
Key Stats
- Today's Range
- $0.79 – $0.85
- 50-Day Range
- $0.65 – $1.12
- 52-Week Range
- $0.55 – $2.22
- Volume
- 124K shs
- Average Volume
- 143K shs
- Market Cap
- $8.85 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 0.21
- Price / Sales
- 71.81
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $123,296
- Net Income
- $-11,954,827
- Net Margin
- -9696.04%
- Return on Equity
- -28.75%
- Debt-to-Equity
- —
About Aprea Therapeutics, Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Related Stocks
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.